New Approach for Nose Job Without Breaking Bones

2 years ago

Ultrasonic Rhinoplasty Rhinoplasty Results Ultrasonic Rhinoplasty Results, 4 Weeks Post-Surgery, Female, Age 30ATLANTA, May 04, 2022 (GLOBE NEWSWIRE) -- Atlanta…

BioCardia to Host Q1 2022 Financial Results and Corporate Update Conference Call on May 11, 2022

2 years ago

SUNNYVALE, Calif., May 04, 2022 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the…

Minerva Neurosciences Reports First Quarter 2022 Financial Results and Business Updates

2 years ago

Company Expects to Submit an NDA for Roluperidone, Subject to FDA Guidance, in the Third Quarter of 2022WALTHAM, Mass., May…

Sarepta Therapeutics to Present at the BofA Securities 2022 Healthcare Conference

2 years ago

CAMBRIDGE, Mass., May 04, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare…

Dyve Biosciences to Present at the UBS Global Healthcare Conference

2 years ago

CAMARILLO, Calif., May 04, 2022 (GLOBE NEWSWIRE) -- Dyve Biosciences, Inc. (“Dyve”), a clinical-stage biotech company applying its proprietary transdermal…

Premier Health Announces the Appointment of Giovanni Garay as Ontario General Manager

2 years ago

MONTREAL, May 04, 2022 (GLOBE NEWSWIRE) -- Premier Health of America Inc. (TSXV: PHA) (the “Corporation” or “Premier Health”), a…

Gracell Biotechnologies to Participate in Three Investor Conferences in May

2 years ago

SAN DIEGO and SUZHOU, China and SHANGHAI, China, May 04, 2022 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”),…

TRACON to Report First Quarter 2022 Financial Results and Corporate Update on May 11, 2022

2 years ago

SAN DIEGO, May 04, 2022 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (Nasdaq: TCON), a clinical stage biopharmaceutical company focused on the…

Phathom Pharmaceuticals Announces Revenue Interest Financing Agreement for Up to $260 Million in Non-Dilutive Capital

2 years ago

Upfront payment of $100 million, an additional $160 million available upon FDA approval of vonoprazan for treatment of erosive esophagitis…